Drug Trial Radar · NCT06126835
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
Last checked: Nov 20, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,828
Planned (sponsor's estimate)
Start
Aug 26, 2024
Primary completion
May 31, 2031
Study completion Jun 30, 2032
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with ulcerative colitis (UC) who were exposed to ozanimod during pregnancy; the second is women with UC exposed to conventional therapy during pregnancy; the third is women with UC exposed to advanced therapy during pregnancy. This study will use data from a large US healthcare claims database.
Conditions
- Ulcerative Colitis
Interventions
OzanimodDrug
Women with UC exposed to ozanimod during pregnancy
Conventional therapyDrug
Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
Advanced therapyDrug
Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of major congenital malformations among infantsTime frame: Up to 10 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
OptumInsight Life Sciences Inc
Eden Prairie, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.